Despite making significant clinical progress, CRISPR Therapeutics (CRSP 6.83%) has been struggling financially in the past three years. The company's shares are down by 24% over this period, while the S&P 500 has gained 41%. The gene-editing specialist has, no doubt, faced some headwinds.However, important catalysts could double its stock price by 2030. For those keeping score at home, that would amount to a compound annual growth rate of about 14.9%, well above the market's historical average returns. Prog ...